论文部分内容阅读
目的验证Ｋ－ｒａｓ基因突变与化疗敏感性之间关系。方法用ＭＴＴ法测定了１７种抗癌药对４３例大肠癌的抑制率，并用聚合酶链反应—限制性片段长度多态性分析法检测大肠癌中Ｋ－ｒａｓ基因突变情况，将其分成Ｋ－ｒａｓ突变组与正常组，分别统计１７种抗癌药在两组中抑制率大小，并进行比较。结果除丝裂霉素、平阳霉素、顺铂外，抗癌药在正常组中的抑制率大于在突变组中的抑制率，其中更生霉素，甲氨喋呤、长春新碱、鬼臼乙叉苷、阿霉素、阿克拉霉素两组存在显著差异。结论肠癌中Ｋ－ｒａｓ基因存在突变时，抗癌药耐药性增加。
Objective To verify the relationship between K-ras gene mutation and chemotherapy sensitivity. Methods MTT assay was used to determine the inhibition rate of 17 anticancer drugs against 43 cases of colorectal cancer. K-ras gene mutation in colorectal cancer was detected by polymerase chain reaction-restriction fragment length polymorphism analysis and divided into K. -ras mutation group and normal group, respectively 17 anticancer drugs in the statistical rate of inhibition in the two groups, and compared. Results In addition to mitomycin, bleomycin, and cisplatin, the inhibitory rate of anticancer drugs in the normal group was greater than that in the mutant group. Among them, dactinomycin, methotrexate, vincristine, and guinea pig There were significant differences between the two groups of ethyl forskolin, doxorubicin, and aclarin. Conclusion When there is a mutation in K-ras gene in colorectal cancer, the anticancer drug resistance increases.